Literature DB >> 34755464

A note on point estimation and interval estimation of the relative treatment effect under a simple crossover design.

Chii-Dean Lin1, Kung-Jong Lui1.   

Abstract

To increase power or reduce the number of patients needed for a parallel groups design, the crossover design has been often used to study treatments for noncurable chronic diseases. However, in the presence of carry-over effect caused by treatments, the commonly-used estimator which ignores the carry-over effect leads to a biased estimator for estimating the treatment effect difference. A two-stage test approach aimed to address carry-over effect proposed was found to be potentially misleading. In this paper, we propose a weighted average of the commonly-used estimator and an unbiased estimator that uses only the first period of the data. We derive an optimal weight that minimizes the mean squared error (MSE) and its modified estimator. We apply Monte Carlo simulation to evaluate the performance of the proposed estimators in a variety of situations. In the simulations, we examine the estimated MSE (EMSE), percentile interval length, and coverage probability calculated from the percentile intervals among considered estimators. Simulation results show that our proposed weighted average estimator and its modified estimator lead to smaller EMSEs on average comparing to the two commonly used estimators. The coverage probabilities using our proposed estimators are reasonably close to the nominal confidence level and the interval lengths are shorter comparing to the use of the unbiased estimator that uses only the first period of the data. We apply an example that was to evaluate the efficacy of two type of bronchodilators for asthma treatment to demonstrate the use of the proposed estimators.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  carry-over effect; mean squared error; parallel groups design; percentile interval; relative treatment effect; simple crossover design

Mesh:

Year:  2021        PMID: 34755464      PMCID: PMC9054161          DOI: 10.1002/pst.2176

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.234


  10 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  Is the 'simple carry-over' model useful?

Authors:  S J Senn
Journal:  Stat Med       Date:  1992-04       Impact factor: 2.373

3.  Problems with the two stage analysis of crossover trials.

Authors:  S J Senn
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Modelling and design of cross-over trials.

Authors:  B Jones; A N Donev
Journal:  Stat Med       Date:  1996-07-15       Impact factor: 2.373

5.  The case for cross-over trials in phase III.

Authors:  S Senn
Journal:  Stat Med       Date:  1997-09-15       Impact factor: 2.373

6.  The performance of the two-stage analysis of two-treatment, two-period crossover trials.

Authors:  P R Freeman
Journal:  Stat Med       Date:  1989-12       Impact factor: 2.373

Review 7.  A critique of recent research on the two-treatment crossover design.

Authors:  J L Fleiss
Journal:  Control Clin Trials       Date:  1989-09

8.  Cross-over trials, carry-over effects and the art of self-delusion.

Authors:  S J Senn
Journal:  Stat Med       Date:  1988-10       Impact factor: 2.373

9.  Carryover and the two-period crossover clinical trial.

Authors:  A R Willan; J L Pater
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

10.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.